Published in J Infect Dis on April 01, 1997
Acquired immunity to malaria. Clin Microbiol Rev (2009) 6.24
White blood cell counts and malaria. J Infect Dis (2005) 3.46
Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol (2011) 2.53
A quantitative analysis of transmission efficiency versus intensity for malaria. Nat Commun (2010) 1.66
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2012) 1.62
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One (2011) 1.47
Diagnosis and treatment based on quantitative PCR after controlled human malaria infection. Malar J (2016) 1.43
Cardiac complication after experimental human malaria infection: a case report. Malar J (2009) 1.35
Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2014) 1.32
Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials. Infect Immun (1999) 1.16
Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis (2013) 1.15
Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One (2010) 1.14
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg (2011) 1.09
Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg (2009) 1.04
Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. Malar J (2014) 1.00
Plasmodium yoelii-infected A. stephensi inefficiently transmit malaria compared to intravenous route. PLoS One (2010) 0.99
Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag (2008) 0.99
Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One (2013) 0.95
Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia. J Infect Dis (2016) 0.94
Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2009) 0.93
A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun (2009) 0.93
The current state of tuberculosis vaccines. Hum Vaccin Immunother (2013) 0.88
Taking a bite out of malaria: controlled human malaria infection by needle and syringe. Am J Trop Med Hyg (2013) 0.88
Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J (2015) 0.87
Malaria sporozoite challenge model comes of age. Pathog Glob Health (2012) 0.86
Viral vector vaccines make memory T cells against malaria. Immunology (2007) 0.86
Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research. Malar J (2014) 0.86
Concomitant infection decreases the malaria burden but escalates relapsing fever borreliosis. Infect Immun (2010) 0.85
Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge. PLoS One (2014) 0.82
Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One (2013) 0.81
Ethical aspects of malaria control and research. Malar J (2015) 0.80
Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. PLoS Negl Trop Dis (2016) 0.80
Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol (2016) 0.76
Clinical manifestations of Plasmodium falciparum malaria. J Infect Dis (1998) 0.75
Leukogram Profile and Clinical Status in vivax and falciparum Malaria Patients from Colombia. J Trop Med (2015) 0.75
The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection. PLoS Comput Biol (2017) 0.75
T follicular helper cells regulate the activation of B lymphocytes and antibody production during Plasmodium vivax infection. PLoS Pathog (2017) 0.75
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med (1983) 11.15
Cell lines derived from late embryonic stages of Drosophila melanogaster. J Embryol Exp Morphol (1972) 9.58
Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med (1995) 8.89
Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science (1984) 8.18
The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med (1976) 7.89
Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis (1997) 6.64
Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet (1994) 6.01
Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev (1984) 5.98
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet (2001) 5.01
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Comparative testing of monoclonal antibodies against Plasmodium falciparum sporozoites for ELISA development. Bull World Health Organ (1987) 4.65
Automated systems for identification of microorganisms. Clin Microbiol Rev (1992) 4.26
Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrob Agents Chemother (1998) 4.24
Summary of an international workshop on typhoid fever. Rev Infect Dis (1986) 4.21
Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci (1973) 4.18
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 3.94
Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science (1989) 3.83
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science (1998) 3.83
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg (1997) 3.61
Role of solid media when used in conjunction with the BACTEC system for mycobacterial isolation and identification. J Clin Microbiol (1991) 3.60
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (1987) 3.51
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 3.46
Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis (2001) 3.43
Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis (1999) 3.38
Fluctuation analysis: the probability distribution of the number of mutants under different conditions. Genetics (1990) 3.32
Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg (1975) 3.32
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol (1990) 3.11
Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet (1991) 3.01
Identification of Plasmodium falciparum-infected mosquitoes by a double antibody enzyme-linked immunosorbent assay. Am J Trop Med Hyg (1984) 3.00
Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet (1987) 2.98
The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet (2000) 2.92
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
A quinoline methanol (WR 30090) for treatment of acute malaria. Antimicrob Agents Chemother (1973) 2.85
Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science (1985) 2.78
Dematiaceous fungi are an increasing cause of human disease. Clin Infect Dis (1996) 2.72
From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on enteropathogenic Escherichia coli. J Infect Dis (1983) 2.71
Suppressive activity of mefloquine in sporozoite-induced human malaria. Antimicrob Agents Chemother (1976) 2.71
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg (1983) 2.57
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis (2001) 2.54
Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science (1985) 2.44
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Primary structure of a Plasmodium falciparum malaria antigen located at the merozoite surface and within the parasitophorous vacuole. J Biol Chem (1988) 2.43
Experimental human infections with Giardia lamblia. J Infect Dis (1987) 2.42
The ecological role of bacteriocins in bacterial competition. Trends Microbiol (1999) 2.42
A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrob Agents Chemother (1999) 2.40
Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg (1984) 2.31
Doxycycline therapy for leptospirosis. Ann Intern Med (1984) 2.29
Bacterial population dynamics in three anopheline species: the impact on Plasmodium sporogonic development. Am J Trop Med Hyg (1996) 2.26
alpha-Globin gene organisation in blacks precludes the severe form of alpha-thalassaemia. Nature (1979) 2.25
Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med (1984) 2.24
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun (1992) 2.23
Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients. J Clin Microbiol (1998) 2.22
Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science (1987) 2.17
Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol (1996) 2.16
Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med (1996) 2.15
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis (1995) 2.10
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg (1986) 2.09
Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science (1989) 2.09
Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science (1988) 2.09
Properties of mouse leukemia viruses. VII. The major viral glycoprotein of friend leukemia virus. Isolation and physicochemical properties. Virology (1974) 2.09
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09
Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem (1986) 2.05
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst (1994) 2.05
A phenanthrene methanol (WR 33063) for treatment of acute malaria. Antimicrob Agents Chemother (1973) 2.05
A shotgun optical map of the entire Plasmodium falciparum genome. Nat Genet (1999) 2.04
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 2.03
Vesicular stomatitis virus replication in human leukocyte cultures: enhancement by phytohemagglutinin. Science (1966) 2.03
Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol (1983) 2.03
Urinary delta-aminolevulinic acid (ALA) levels in lead poisoning. I. A modified method for the rapid determination of urinary delta-aminolevulinic acid using disposable ion-exchange chromatography columns. Arch Environ Health (1967) 2.01
Increased incidence of Streptococcus agalactiae. Vet Rec (2002) 2.01
Telepathology overview: from concept to implementation. Hum Pathol (2001) 2.01
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis (1998) 2.00
An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg (1990) 2.00
Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A (1992) 2.00
Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg (1984) 1.99
A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol (1987) 1.95
Haemophilus influenzae can use human transferrin as a sole source for required iron. Infect Immun (1985) 1.94